Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 2
2006 1
2009 2
2011 3
2012 1
2015 3
2016 4
2017 2
2018 2
2019 3
2020 1
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

22 results
Results by year
Filters applied: . Clear all
Page 1
Risk-Targeted Lung Cancer Screening: A Cost-Effectiveness Analysis.
Kumar V, Cohen JT, van Klaveren D, Soeteman DI, Wong JB, Neumann PJ, Kent DM. Kumar V, et al. Ann Intern Med. 2018 Feb 6;168(3):161-169. doi: 10.7326/M17-1401. Epub 2018 Jan 2. Ann Intern Med. 2018. PMID: 29297005 Free PMC article.
TIME HORIZON: Lifetime. PERSPECTIVE: Health care sector. INTERVENTION: Risk-targeted versus NLST-based screening. ...LIMITATION: Our model did not account for all correlated differences between lung cancer mortality risk and quality of life
TIME HORIZON: Lifetime. PERSPECTIVE: Health care sector. INTERVENTION: Risk-targeted versus NLST-based screening
Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial.
Gæde P, Oellgaard J, Carstensen B, Rossing P, Lund-Andersen H, Parving HH, Pedersen O. Gæde P, et al. Diabetologia. 2016 Nov;59(11):2298-2307. doi: 10.1007/s00125-016-4065-6. Epub 2016 Aug 16. Diabetologia. 2016. PMID: 27531506 Free PMC article. Clinical Trial.
AIMS/HYPOTHESIS: The aim of this work was to study the potential long-term impact of a 7.8 years intensified, multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria in terms of gained years of life and years free from incid …
AIMS/HYPOTHESIS: The aim of this work was to study the potential long-term impact of a 7.8 years intensified, multifactorial intervention
Cost-Effectiveness of Transitional Care Services After Hospitalization With Heart Failure.
Blum MR, Øien H, Carmichael HL, Heidenreich P, Owens DK, Goldhaber-Fiebert JD. Blum MR, et al. Ann Intern Med. 2020 Feb 18;172(4):248-257. doi: 10.7326/M19-1980. Epub 2020 Jan 28. Ann Intern Med. 2020. PMID: 31986526
DATA SOURCES: Randomized controlled trials, clinical registries, cohort studies, Centers for Disease Control and Prevention life tables, Centers for Medicare & Medicaid Services data, and National Inpatient Sample (Healthcare Cost and Utilization Project) …
DATA SOURCES: Randomized controlled trials, clinical registries, cohort studies, Centers for Disease Control and Prevention
The cost-effectiveness of canakinumab for secondary prevention of cardiovascular disease: The Australian healthcare perspective.
Zomer E, Liew D, Tonkin A, Trauer JM, Ademi Z. Zomer E, et al. Int J Cardiol. 2019 Jun 15;285:1-5. doi: 10.1016/j.ijcard.2019.01.037. Epub 2019 Jan 15. Int J Cardiol. 2019. PMID: 30686493
BACKGROUND: Canakinumab is a fully human monoclonal antibody targeting interleukin-1beta. It is currently indicated for use in those with rheumatologic disorders due to its anti-inflammatory properties, and was recently shown to be beneficial for the secondary preventio
BACKGROUND: Canakinumab is a fully human monoclonal antibody targeting interleukin-1beta. It is currently indicated for use in those …
Cost-Effectiveness of Alirocumab: A Just-in-Time Analysis Based on the ODYSSEY Outcomes Trial.
Kazi DS, Penko J, Coxson PG, Guzman D, Wei PC, Bibbins-Domingo K. Kazi DS, et al. Ann Intern Med. 2019 Feb 19;170(4):221-229. doi: 10.7326/M18-1776. Epub 2019 Jan 1. Ann Intern Med. 2019. PMID: 30597485
TIME HORIZON: Lifetime. PERSPECTIVE: U.S. health system. INTERVENTION: Alirocumab or ezetimibe added to statin therapy. OUTCOME MEASURES: Incremental cost-effectiveness ratio in 2018 U.S. dollars per quality-adjusted life-year (QAL
TIME HORIZON: Lifetime. PERSPECTIVE: U.S. health system. INTERVENTION: Alirocumab or ezetimibe added to statin t
Cost-effectiveness and health-related outcomes of screening for hepatitis C in Korean population.
Kim KA, Chung W, Choi HY, Ki M, Jang ES, Jeong SH. Kim KA, et al. Liver Int. 2019 Jan;39(1):60-69. doi: 10.1111/liv.13930. Epub 2018 Aug 10. Liver Int. 2019. PMID: 29998565
Screening was performed by integration of the anti-HCV test into the National Health Examination Program. From a healthcare system's perspective, the cost-utility and the impact on HCV-related health events of one-time anti-HCV screening and DAA treatm …
Screening was performed by integration of the anti-HCV test into the National Health Examination Program. From a healthcare system' …
Evidence to inform the future for maternal and newborn health.
Lawn JE, Blencowe H, Kinney MV, Bianchi F, Graham WJ. Lawn JE, et al. Best Pract Res Clin Obstet Gynaecol. 2016 Oct;36:169-183. doi: 10.1016/j.bpobgyn.2016.07.004. Epub 2016 Jul 28. Best Pract Res Clin Obstet Gynaecol. 2016. PMID: 27707540
Despite the impressive progress gains for maternal and child health during the Millennium Development Goals era, over 5.6 million women and babies died in 2015 due to complications during pregnancy, birth and in the first month of life. ...Priority actions in …
Despite the impressive progress gains for maternal and child health during the Millennium Development Goals era, over 5.6 mill …
The impact of Thailand's public health response to the HIV epidemic 1984-2015: understanding the ingredients of success.
Siraprapasiri T, Ongwangdee S, Benjarattanaporn P, Peerapatanapokin W, Sharma M. Siraprapasiri T, et al. J Virus Erad. 2016 Nov 28;2(Suppl 4):7-14. J Virus Erad. 2016. PMID: 28275444 Free PMC article.
CONCLUSIONS: Thailand's AIDS response has prevented needless morbidity and mortality due to the HIV epidemic. In the context of Thailand's ageing population, it is faced with the twin challenges of maintaining life-long quality services among HI …
CONCLUSIONS: Thailand's AIDS response has prevented needless morbidity and mortality due to the HIV epidemic. In the context o …
Age-Dependent Impact of Medication Underuse and Strategies for Improvement.
Meid AD, Haefeli WE. Meid AD, et al. Gerontology. 2016;62(5):491-9. doi: 10.1159/000443477. Epub 2016 Feb 5. Gerontology. 2016. PMID: 26844916
METHODS: In the competing risk framework, we obtained the population's life course from life tables, combined it with effect estimates quantifying the real-world effectiveness of secondary prevention, and compared the outcome of patients not rec
METHODS: In the competing risk framework, we obtained the population's life course from life tables, combined it
Assessing the clinical and economic impact of increasing treatment uptake in chronic hepatitis B infection using a Markov model.
Chinnaratha MA, Kaambwa B, Woodman RJ, Fraser RJ, Wigg AJ. Chinnaratha MA, et al. J Gastroenterol Hepatol. 2017 Jul;32(7):1370-1377. doi: 10.1111/jgh.13679. J Gastroenterol Hepatol. 2017. PMID: 28002881
We estimated the incremental cost per quality adjusted life year gained using the prevented number of deaths, hepatocellular carcinoma, and liver transplants. RESULTS: Scenario 3 was associated with the lowest mean cost/person over 10 years (AU$ …
We estimated the incremental cost per quality adjusted life year gained using the prevented number of deaths
22 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback